In addition to Citi, Dexcom also received a Buy from Raymond James’s Jayson Bedford in a report issued yesterday. However, today, Barclays maintained a Hold rating on Dexcom (NASDAQ: DXCM). The ...

Investors with a lot of money to spend have taken a bullish stance on DexCom DXCM. And retail traders should know. We noticed this today when the positions showed up on publicly available options ...

DexCom (NasdaqGS:DXCM) experienced an 12% decline over the past week, during which the company transitioned its audit from Ernst & Young to Deloitte & Touche, and appointed Jon Coleman as Chief ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Dexcom ( DXCM – Research Report ), with a price target of $98.00. The company’s shares closed yesterday at ...

Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last week citing issues at two of its manufacturing facilities. The warning ...

In its fourth quarter 2024 investor letter, Sands Capital Select Growth Fund emphasized stocks such as DexCom, Inc. (NASDAQ:DXCM). DexCom, Inc. (NASDAQ:DXCM) is a medical device company that ...

Cheng Xin / Getty Images DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants. The maker of glucose monitoring devices said ...

DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...